Cannabis News Box

Germany’s pensioner-dominated medical cannabis market demanded 1,650 pounds of flower in Q1 2019

Germany’s pensioner-dominated medical cannabis market demanded 1,650 pounds of flower in Q1 2019

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 8, 2019

Older patients are steering Germany’s medical cannabis market, with the biggest patient group comprising residents aged between 50 and 59 years of age.  This is according to the latest data published by the German government, which also highlights swelling market demand for cannabis flower; in the first quarter of 2019 (Q1 2019), the European country’s flower imports exceeded 1,650 pounds. Considering those figur...

Big Pharma, Big Tobacco betting big on legal weed

Big Pharma, Big Tobacco betting big on legal weed

Bethan Rose Jenkins, Cannabis News Writer/Editorial

February 28, 2019

Major pharmaceutical drug companies are getting involved in legal cannabis, albeit a bit discreetly. According to recent reports, patents are being snapped up left, right and center, while some pharmaceutical giants are dishing out all their dollar on research and development (R&D). So long as a drug is deemed...

Cannabis study: Whole-plant cannabis is more powerful at treating epilepsy than CBD

Cannabis study: Whole-plant cannabis is more powerful at treating epilepsy than CBD

Bethan Rose Jenkins, Cannabis News Writer/Editorial

October 5, 2018

The number of cannabis studies demonstrating the plant’s medical potency for the treatment of epilepsy, among many other ailments, is rapidly increasing.  In June, the Food and Drug Administration (FDA) approved a cannabis-based medicine for epileptic patients, known as Epidiolex. The drug, which w...

Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually

Cannabis-based epilepsy treatment Epidiolex will cost $32,500 annually

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 29, 2018

Epilepsy sufferers may never have to worry about enduring bouts of life-threatening seizures ever again, thanks to the Food and Drug Administration (FDA) approving the world’s first ever cannabis-derived medication for the treatment of two rare types of pediatric epilepsy. The discussion surrounding ...

Great Britain prepares to legalize cannabis for medicinal use

Great Britain prepares to legalize cannabis for medicinal use

Bethan Rose Jenkins, Cannabis News Writer/Editorial

August 3, 2018

Medical cannabis is set to become available on prescription in the UK after the government approved a law to permit medicines derived from the cannabis plant. According to the Home Office, cannabis-based medicines can be legally prescribed by general practitioners “by the autumn.” “Following advice f...

CEO of GW Pharma talks about Epidiolex getting FDA approval

CEO of GW Pharma talks about Epidiolex getting FDA approval

Bethan Rose Jenkins, Cannabis News Writer/Editorial

July 2, 2018

On Monday, Justin Gover hit a milestone in his career. He is the CEO of GW Pharmaceuticals – a company that created a cannabis-based medicine called Epidiolex. Not only is Epidiolex being used to treat two forms of epilepsy but also, it is non-psychoactive, what with it containing the cannabis com...

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Will Epidiolex be the first cannabis-based drug to be approved as an epilepsy treatment?

Bethan Rose Jenkins, Cannabis News Writer/Editorial

May 3, 2018

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment Epidiolex will undergo FDA review this June. Things are looking hopeful, with a panel of 13 advisors...

FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex

FDA gives positive review for GW Pharmaceuticals’ cannabis-based medicine Epidiolex

Bethan Rose Jenkins, Cannabis News Writer/Editorial

April 19, 2018

Epidiolex, a cannabis-based treatment for epilepsy from GW Pharmaceuticals, received a positive review from staff at the Federal Drug Administration (FDA) on Tuesday. GW Pharmaceuticals provided “substantial evidence” to prove the drug’s suitability for treating two rare types of epilepsy. ...

GW Pharmaceuticals